Back
MicroStrategy 10K Form
Buy
62
MSTR
MicroStrategy
Last Price:
1,706.00
Seasonality Move:
-5.09%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-01 | 10Q | MSTR/MicroStrategy Quarterly |
2023-08-01 | 10Q | MSTR/MicroStrategy Quarterly |
2023-05-01 | 10Q | MSTR/MicroStrategy Quarterly |
2022-11-01 | 10Q | MSTR/MicroStrategy Quarterly |
2022-08-02 | 10Q | MSTR/MicroStrategy Quarterly |
2022-05-03 | 10Q | MSTR/MicroStrategy Quarterly |
Receive MSTR News And Ratings
See the #1 stock for the next 7 days that we like better than MSTR
MSTR Financial Statistics
Sales & Book Value
Annual Sales: | $496.26M |
---|---|
Cash Flow: | $-1.21B |
Price / Cash Flow: | 0 |
Annual Sales: | $128.35 |
Price / Book: | 13.36 |
Profitability
EPS (TTM): | 28.18000 |
---|---|
Net Income (TTM): | $429.12M |
Gross Margin: | $386.32M |
Return on Equity: | 55.23% |
Return on Assets: | 12.67% |
MicroStrategy Earnings Forecast
Key MicroStrategy Financial Ratios
- The Gross Profit Margin over the past 27 years for MSTR is 77.85%.
- The Selling, General & Administrative Expenses for MSTR have been equal to 53.40% of Gross Profit Margin.
- The Research & Development expenses have been 24.29% of Revenue.
- The Interest Expense is 11.41% of Operating Income.
- The Net Earning history of MSTR is 86.47% of Total Revenues.
- Per Share Earnings over the last 27 years have been positive in 12 years.
MicroStrategy Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Software - Application |
Sector: | Technology |
Current Symbol: | MSTR |
CUSIP: | 594972 |
Website: | microstrategy.com |
Debt
Debt-to-Equity Ratio: | 1.01 |
---|---|
Current Ratio: | 0.83 |
Quick Ratio: | 0.71 |
Price-to-Earnings
Trailing P/E Ratio: | 64.52 |
---|---|
Forward P/E Ratio: | 1469.45 |
MSTR Technical Analysis vs Fundamental Analysis
Buy
62
MicroStrategy (MSTR)
is a Buy
Is MicroStrategy a Buy or a Sell?
-
MicroStrategy stock is rated a Buy
The current MicroStrategy [MSTR] share price is $1,704.56. The Score for MSTR is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.